The Evidence-Based Analysis of Treatment for Chronic Myeloid Leukemia: An Introduction to Its Methods and Clinical Implications

I N THIS ISSUE OF BLOOD, a panel sponsored by the American Society of Hematology (ASH) publishes its analysis of data on selected modalities used for treatment of the chronic phase of chronic myeloid leukemia (CML).[1][1] The text is long, and the data presented are complex and arrayed in elaborate